Group 1 - The core viewpoint of the articles highlights the successful implementation and effectiveness of the monoclonal antibody Nirsevimab in preventing RSV-related respiratory infections in infants in China, with a reported efficacy of 81% for outpatient visits and 82% for hospitalizations [1][2] - The real-world study conducted across multiple regions in China, including Beijing, Shanghai, and Guangdong, provides localized data supporting the safety and effectiveness of Nirsevimab for Chinese infants [1] - The introduction of Nirsevimab in Shanghai has expanded its availability to public hospitals, private hospitals, and community health service centers, allowing parents to access RSV prevention more conveniently [2] Group 2 - The Shanghai Health Commission plans to expand the use of RSV monoclonal antibodies to 36 additional pilot units by June 2025, indicating a shift towards a more proactive and inclusive immunization strategy for infants [2] - A new respiratory health handbook for infants has been released, providing parents with authoritative and practical health guidelines on common respiratory diseases, including RSV [2] - Sanofi showcased a combined vaccine for RSV and HMPV at the innovation pipeline exhibition, aiming to address multiple respiratory viruses that pose risks to vulnerable populations, particularly the elderly [3]